Tempest Therapeutics, Inc. (TPST) Misses Q2 EPS by 2c
Tweet
Share
E-mailGet Alerts TPST Hot Sheet
Join SI Premium – FREE
Tempest Therapeutics, Inc. (NASDAQ: TPST) reported Q2 EPS of ($0.54), $0.02 worse than the analyst estimate of ($0.52).
For earnings history and earnings-related data on Tempest Therapeutics, Inc. (TPST) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
- SPS Commerce hires Morgan Stanley to explore sale amid activist push - Reuters
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
